Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection

Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis

(2020) Chakradhar V Lagishetty et al.   CTS-Clinical and Translational Science

Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States

(2020) Lucia R.I. Millham et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir

(2020) Yagai Bouba et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals

(2020) Luciana Lepore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients

(2020) Francesco Saladini et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

(2020) Michael Kozal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Choosing appropriate pharmacotherapy for drug-resistant HIV

(2019) Amedeo Capetti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, HIV‐seronegative participants

(2019) Katy Moore et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir

(2018) Max Lataillade et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir

(2018) Elodie Alessandri-Gradt et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir

(2018) Tao Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

HIV Clinical Updates: New Single-Tablet Regimens

(2018) Jamielynn C. Sebaaly et al.   ANNALS OF PHARMACOTHERAPY

Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV

(2018) Yijun Zhang et al.   JOURNAL OF VIROLOGY

Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir

(2017) Nicholas A. Meanwell et al.   JOURNAL OF MEDICINAL CHEMISTRY

HIV drug resistance against strand transfer integrase inhibitors

(2017) Kaitlin Anstett et al.   Retrovirology

Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment

(2017) Heather Sevinsky et al.   Open Forum Infectious Diseases

Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529

(2016) Ishani Landry et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial

(2016) Melanie Thompson et al.   ANTIVIRAL THERAPY

Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects

(2015) Li Zhu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

BMS-663068, a safe and effective HIV-1 attachment inhibitor

(2015) Ester Ballana et al.   Lancet HIV

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

(2015) Jacob P Lalezari et al.   Lancet HIV

A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large protease/reverse-transcriptase and co-receptor tropism database from 2003 to 2012

(2014) Agnes C Paquet et al.   ANTIVIRAL THERAPY

HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis

(2014) Cynthia Brinson et al.   Journal of the International AIDS Society

Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors

(2013) Zhufang Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068

(2013) Neelanjana Ray et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068

(2013) N. Zhou et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In VitroAntiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068

(2012) Beata Nowicka-Sans et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects

(2012) R. E. Nettles et al.   JOURNAL OF INFECTIOUS DISEASES